Clinical trial NCT03121014: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
Official title: A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes
Lead sponsor: University of Illinois at Chicago
Sponsor class: OTHER
First posted: 2017-04-19
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is a Phase II clinical trial. Patients will receive intensity modulated total marrow irradiation (TMI) at a dose of 9 Gy with standard myeloablative fludarabine/ i.v. targeted busulfan (FluBu) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT).

Detailed description: Patients will receive the following conditioning regimen: fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate (see Section 8). Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.

Eligibility criteria: Inclusion Criteria:

1. Age 18-65 years
2. Patients with AML or MDS who meet the following criteria:

   a. Relapsed or refractory AML (including AML in CR2)

   b. Poor-risk AML in first remission, with remission defined as \<5% bone marrow blasts morphologically:
   * AML arising from MDS or a myeloproliferative disorder, or secondary AML
   * Poor risk molecular features including presence of FLT3 internal tandem duplication mutation.
   * Poor-risk cytogenetics: Monosomal karyotype, complex karyotype (\> 3 abnormalities), inv(3), t(3;3), t(6;9), MLL rearrangement with the exception of t(9;11), or abnormalities of chromosome 5 or 7

     c. Primary refractory disease

     d. MDS with at least one of the following poor-risk features:
   * Poor-risk cytogenetics including 3q abnormalities, 7/7q minus or complex cytogenetics (\>3 abnormalities)
   * Current or previous INT-2 or high IPSS score
   * Treatment-related MDS
   * MDS diagnosed before age 21 years
   * Progression on or lack of response to standard DNA-methyltransferase inhibitor therapy
   * Life-threatening cytopenias, including those requiring regular PRBC or platelet transfusions e. CML with a history of accelerated or blast phase
3. Patients must have a related or unrelated peripheral blood stem cell donor as follows:

   1. Sibling donor must be a 6/6 match for HLA-A, -B at intermediate (or higher) resolution and -DRB1 at high resolution using DNA based typing
   2. Unrelated donors must be at least 7/8 match at HLA-A, -B, -C and DRB1 at high resolution using DNA-based typing

Exclusion criteria:

1. Presence of significant co morbidity as shown by:

   1. Left ventricular ejection fraction \< 50%
   2. Creatinine clearance \<30ml/min
   3. Bilirubin \> 2.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST \> 5 x ULN
   4. FEV1 and FVC \< 50% of predicted or DLCO \<50% of predicted once corrected for anemia

   f. Karnofsky score \<70 (appendix C)

   g. Hematopoietic cell transplantation comorbidity index \>3

   h. Active viral hepatitis or HIV infection

   j. Cirrhosis
2. Pregnancy
3. Patients unable to sign informed consent
4. Patient who have previously received radiation to \>20% of bone marrow containing areas.

4. DONOR ELIGIBILITY AND SELECTION

4.1. Donor Selection

Donor evaluation and selection is by standard for normal clinical practice. No study procedures are to be performed on donors. All donors must be willing to donate peripheral blood stem cells and meet institutional or NMDP criteria for donation.

The following prioritization will be used when selecting donors:

1. When possible, an HLA compatible sibling will be used as a donor.
2. For patients who do not have an HLA compatible sibling, an unrelated donor will be used
3. 8/8 matched unrelated donors are preferred over single antigen mismatched donors.

If more than one potential volunteer unrelated donor is considered suitable further selection of the most suitable donor is at the discretion of the treating physician. The following serves only as a guide for prioritization:

1. Age of donor (18-24 \> 25-34 \> 35-44 \> 45+)
2. Sex and parity of donor (male \> female, nulliparous female \> parous, multiparous female)
3. Cytomegalovirus (CMV) status, if recipient is CMV seronegative (CMV- \> CMV+)

Primary outcomes:
measure: Relapse free survival of approximately 30% in high-risk patients conditioned with the Fludarabine/ Busulfan regimen
timeFrame: Up to 1 year
Secondary outcomes:
measure: Relapse free survival
timeFrame: Up to 1 year
measure: Overall survival
timeFrame: Up to 1 year
measure: Transplant related mortality rate
timeFrame: Up to 1 year
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Illinois at Chicago
state: Illinois
Study officials:
affiliation: University of Illinois at Chicago
name: Damiano Rondelli, MD
role: PRINCIPAL_INVESTIGATOR
References: